Keep pulling the thread on Daniel O'Day.
Gilead's lenacapivir is administered twice a year and was nearly 100% effective at preventing HIV in trials.
Gilead voluntarily licensed lenacapivir to generic manufacturers with no royalties as part of its societal responsibility.
Gilead is producing lenacapivir at no profit and working with the Global Fund and PEPFAR to distribute it to 120 low and low-middle income countries.
The interim bridging commitment for lenacapivir distribution with the Global Fund and PEPFAR has been increased from a target of two million people to three million people over the next three years.
Daniel O'Day believes that within his lifetime, it will be possible to talk about HIV in the past tense.
Cell therapy is achieving curative responses in patients with large B-cell lymphoma, a disease that previously had a life prognosis of approximately six months.
The scientific concept of an "immune reset" could potentially eradicate a host of autoimmune diseases.
In the U.S. healthcare system, 50 cents of every dollar spent on a medicine goes to intermediaries not involved in the drug's discovery or development.
There are 1.3 million new HIV diagnoses globally each year.
Two-thirds of people living with HIV reside in sub-Saharan Africa.
Of the people living with HIV in sub-Saharan Africa, two-thirds are women and adolescent girls.
Gilead made lenacapivir available in the first sub-Saharan African country five months after its approval in the United States.